A mini review: Role of novel biomarker for kidney disease of future study

Palash Mitra , Sahadeb Jana , Suchismita Roy
{"title":"A mini review: Role of novel biomarker for kidney disease of future study","authors":"Palash Mitra ,&nbsp;Sahadeb Jana ,&nbsp;Suchismita Roy","doi":"10.1016/j.abst.2025.02.002","DOIUrl":null,"url":null,"abstract":"<div><div>In the world, kidney disease is most common cause of death. Primary care physicians must conduct appropriate diagnosis, and management in order to avoid detrimental consequences linked to death as well as end-stage kidney disease. In this scenario biomarkers can detect renal pathology more accurately and early than currently known biomarkers, including serum creatinine, estimated glomerular filtration rate and urine albumin, they hold out hope for bettering the care of individuals with kidney illnesses. Nowadays, nephrology is concentrating extensively on finding novel indicators of acute stage of kidney disease in order to prevent further complications from chronic kidney disease as well as end-stage renal disease. The best treatment targets for a particular patient or illness context may also be determined with the use of proteomic and genomic biomarkers. Therefore, current advancements in the study of important biomarkers including tumor necrosis factor, transforming growth factor, interleukin −1, interleukin-18, nephrin, uromodulin, collagen, osteopontin, NGAL and Dickkopf-3 are linked to different aspects of renal injury. Prognosis and risk classification can be enhanced by a variety of proteome and genome biomarkers that are linked to different pathophysiological processes that follow renal damage.</div></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"7 ","pages":"Pages 65-75"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in biomarker sciences and technology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2543106425000067","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

In the world, kidney disease is most common cause of death. Primary care physicians must conduct appropriate diagnosis, and management in order to avoid detrimental consequences linked to death as well as end-stage kidney disease. In this scenario biomarkers can detect renal pathology more accurately and early than currently known biomarkers, including serum creatinine, estimated glomerular filtration rate and urine albumin, they hold out hope for bettering the care of individuals with kidney illnesses. Nowadays, nephrology is concentrating extensively on finding novel indicators of acute stage of kidney disease in order to prevent further complications from chronic kidney disease as well as end-stage renal disease. The best treatment targets for a particular patient or illness context may also be determined with the use of proteomic and genomic biomarkers. Therefore, current advancements in the study of important biomarkers including tumor necrosis factor, transforming growth factor, interleukin −1, interleukin-18, nephrin, uromodulin, collagen, osteopontin, NGAL and Dickkopf-3 are linked to different aspects of renal injury. Prognosis and risk classification can be enhanced by a variety of proteome and genome biomarkers that are linked to different pathophysiological processes that follow renal damage.
综述:未来研究中新型肾脏疾病生物标志物的作用
在世界上,肾脏疾病是最常见的死亡原因。初级保健医生必须进行适当的诊断和管理,以避免与死亡和终末期肾脏疾病相关的有害后果。在这种情况下,生物标志物可以比目前已知的生物标志物(包括血清肌酐、肾小球滤过率和尿白蛋白)更准确、更早地检测肾脏病理,它们有望更好地治疗肾脏疾病患者。为了预防慢性肾脏疾病和终末期肾脏疾病的进一步并发症,肾脏病学正在广泛关注寻找肾脏疾病急性期的新指标。针对特定患者或疾病背景的最佳治疗靶点也可以通过使用蛋白质组学和基因组生物标志物来确定。因此,肿瘤坏死因子、转化生长因子、白细胞介素-1、白细胞介素-18、肾素、尿调素、胶原蛋白、骨桥蛋白、NGAL和Dickkopf-3等重要生物标志物的研究进展与肾损伤的不同方面有关。预后和风险分类可以通过与肾损伤后不同病理生理过程相关的各种蛋白质组和基因组生物标志物来增强。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advances in biomarker sciences and technology
Advances in biomarker sciences and technology Biotechnology, Clinical Biochemistry, Molecular Medicine, Public Health and Health Policy
自引率
0.00%
发文量
0
审稿时长
20 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信